Oyster Point Pharma, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-02-21: Study NCT06329687; Company role Lead sponsor; Phase Phase 4; Status Terminated.
- 2023-06-14: Study NCT05918406; Company role Lead sponsor; Phase Phase 4; Status Completed.
- 2023-05-01: Study NCT05700422; Company role Collaborator; Phase Phase 4; Status Completed.
- 2022-12-07: Study NCT05576415; Company role Collaborator; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-02-21 | NCT06329687 A Study Evaluating the Safety of the Nasal Pump | Lead sponsor | Phase 4 | Terminated Results posted | Dry Eye; Kerato Conjunctivitis Sicca | 5 | 2024-02-28 |
| 2023-06-14 | NCT05918406 Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya | Lead sponsor | Phase 4 | Completed Results posted | Dry Eye; Keratoconjunctivitis Sicca | 30 | 2023-08-18 |
| 2023-05-01 | NCT05700422 Nasal Spray Study in Sjogren's Dry Eye Disease | Collaborator Lead: University of Pennsylvania | Phase 4 | Completed Results posted | Sjogren's Syndrome; Dry Eye | 39 | 2023-08-31 |
| 2022-12-07 | NCT05576415 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease | Collaborator Lead: Corxel Pharmaceuticals | Phase 1 | Completed | Dry Eye Disease | 9 | 2023-04-27 |
| 2022-07-22 | NCT05378945 Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease | Collaborator Lead: Corxel Pharmaceuticals | Phase 3 | Completed | Dry Eye Disease | 340 | 2023-04-04 |
| 2022-07-01 | NCT05566717 An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity | Collaborator Lead: Medical Center Ophthalmology Associates | Observational | Unknown | Diabetic Retinopathy; Neurotrophic Keratitis | 50 | 2022-10-31 |
| 2021-06-17 | NCT04957758 Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy | Lead sponsor | Phase 2 | Completed Results posted | Neurotrophic Keratopathy | 113 | 2023-04-28 |
| 2019-08-26 | NCT04072146 Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline | Lead sponsor | Phase 1 | Completed Results posted | Healthy Subjects | 22 | 2019-11-15 |
| 2019-07-23 | NCT04036292 Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease | Lead sponsor | Phase 3 | Completed Results posted | Dry Eye Disease (DED) | 758 | 2021-02-05 |
| 2019-02-18 | NCT03873246 Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study) | Lead sponsor | Phase 2 | Completed Results posted | Dry Eye Disease | 123 | 2020-01-07 |
| 2018-09-25 | NCT03688802 Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation | Lead sponsor | Phase 2 | Completed Results posted | Dry Eye Disease | 18 | 2019-09-30 |
| 2018-08-15 | NCT03920215 Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | Long Term Follow up Dry Eye Disease | 101 | 2019-09-20 |
| 2018-08-15 | NCT03636061 Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease | Lead sponsor | Phase 2 | Completed Results posted | Dry Eye Disease | 182 | 2018-09-26 |
| 2018-08-14 | NCT03633461 Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study) | Lead sponsor | Phase 2 | Completed Results posted | Dry Eye Disease | 53 | 2018-09-20 |
| 2018-02-27 | NCT03452397 Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study) | Lead sponsor | Phase 2 | Completed Results posted | Dry Eye Disease | 165 | 2018-04-27 |